Abcellera Biologics, Inc. ((ABCL)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AbCellera Biologics Inc. is conducting a Phase 1 clinical study titled ‘A First-in-Human Phase 1 Study of ABCL635 in Healthy Participants and in Postmenopausal Women With Moderate-to-Severe Vasomotor Symptoms’. The study aims to evaluate the effects of ABCL635, a biological intervention, on vasomotor symptoms (VMS) associated with menopause, focusing on safety, tolerability, and pharmacokinetic and pharmacodynamic parameters.
The intervention being tested is ABCL635, administered via subcutaneous injection. It is designed to address moderate-to-severe vasomotor symptoms in postmenopausal women, with the goal of reducing the frequency and severity of these symptoms.
This interventional study uses a randomized, parallel assignment model with triple masking (participant, care provider, investigator) to ensure unbiased results. The primary purpose is treatment, assessing both single and multiple doses of ABCL635.
The study began on July 16, 2025, with a recent update on September 16, 2025. These dates are crucial as they indicate the study’s progress and current recruitment status, which is ongoing.
The market implications of this study are significant for AbCellera Biologics Inc. Successful results could enhance the company’s stock performance and attract positive investor sentiment, especially in the competitive field of menopause-related treatments.
The study is currently recruiting, with further details available on the ClinicalTrials portal.